Tango Therapeutics/$TNGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tango Therapeutics
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Ticker
$TNGX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
155
ISIN
US87583X1090
Website
TNGX Metrics
BasicAdvanced
$660M
-
-$1.21
1.03
-
Price and volume
Market cap
$660M
Beta
1.03
52-week high
$12.02
52-week low
$1.03
Average daily volume
3.3M
Financial strength
Current ratio
6.262
Quick ratio
6.034
Long term debt to equity
20.462
Total debt to equity
22.156
Profitability
EBITDA (TTM)
-143.374
Gross margin (TTM)
-247.15%
Net profit margin (TTM)
-322.67%
Operating margin (TTM)
-355.87%
Effective tax rate (TTM)
-0.15%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
-26.79%
Return on equity (TTM)
-61.35%
Valuation
Price to revenue (TTM)
16.307
Price to book
3.95
Price to tangible book (TTM)
3.95
Price to free cash flow (TTM)
-4.917
Free cash flow yield (TTM)
-20.34%
Free cash flow per share (TTM)
-123.86%
Growth
Revenue change (TTM)
10.09%
Earnings per share change (TTM)
7.46%
3-year revenue growth (CAGR)
4.02%
3-year earnings per share growth (CAGR)
7.54%
What the Analysts think about TNGX
Analyst ratings (Buy, Hold, Sell) for Tango Therapeutics stock.
Bulls say / Bears say
Tango Therapeutics has initiated a Phase 1/2 trial combining TNG462 with Revolution Medicines' RAS(ON) inhibitors, targeting RAS-mutant MTAP-deleted pancreatic or lung cancers, potentially expanding their market reach. (tangotx.com)
The company received Orphan Drug Designation for TNG462 in pancreatic cancer, which may expedite development and provide market exclusivity upon approval. (tangotx.com)
Analysts maintain a 'Buy' consensus with an average 12-month target price of $13.14, indicating confidence in the company's growth prospects. (americanbankingnews.com)
Tango Therapeutics laid off approximately 20% of its staff to extend its cash runway, which may indicate financial challenges. (biopharmadive.com)
The company ceased development of its key drug candidate, TNG348, due to observed liver function abnormalities in trial participants, potentially impacting its pipeline. (investing.com)
Tango reported a net loss of $37.7 million in Q4 2024, an increase from the $30.8 million loss in the same period in 2023, reflecting ongoing financial pressures. (tangotx.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
TNGX Financial Performance
Revenues and expenses
TNGX Earnings Performance
Company profitability
TNGX News
AllArticlesVideos
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
GlobeNewsWire·3 weeks ago
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
GlobeNewsWire·2 months ago
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tango Therapeutics stock?
Tango Therapeutics (TNGX) has a market cap of $660M as of July 16, 2025.
What is the P/E ratio for Tango Therapeutics stock?
The price to earnings (P/E) ratio for Tango Therapeutics (TNGX) stock is 0 as of July 16, 2025.
Does Tango Therapeutics stock pay dividends?
No, Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders as of July 16, 2025.
When is the next Tango Therapeutics dividend payment date?
Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Tango Therapeutics?
Tango Therapeutics (TNGX) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.